ProductsPF-04217329 - Lowest Dose + PF-04217329 - Low Dose + PF-04217329 - Middle Dose + PF-04217329 - High Middle Dose + PF-04217329 - High Dose + PF-4217329 - Highest Dose + PF-04217329 - Vehicle + Latanoprost Vehicle + PF-04217329 - Low Dose + Latanoprost Vehicle + PF-04217329 - Middle Dose + Latanoprost Vehicle + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - Low Dose + Latanoprost 0.005% + PF-04217329 - Middle Dose + Latanoprost 0.005% + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - Vehicle

PF-04217329 - Lowest Dose + PF-04217329 - Low Dose + PF-04217329 - Middle Dose + PF-04217329 - High Middle Dose + PF-04217329 - High Dose + PF-4217329 - Highest Dose + PF-04217329 - Vehicle + Latanoprost Vehicle + PF-04217329 - Low Dose + Latanoprost Vehicle + PF-04217329 - Middle Dose + Latanoprost Vehicle + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - Low Dose + Latanoprost 0.005% + PF-04217329 - Middle Dose + Latanoprost 0.005% + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - Vehicle

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Primary Open-Angle Glaucoma

Conditions

Primary Open-Angle Glaucoma, Ocular Hypertension

Trial Timeline

Dec 11, 2007 → Jun 26, 2009

NCT ID

NCT00572455

About PF-04217329 - Lowest Dose + PF-04217329 - Low Dose + PF-04217329 - Middle Dose + PF-04217329 - High Middle Dose + PF-04217329 - High Dose + PF-4217329 - Highest Dose + PF-04217329 - Vehicle + Latanoprost Vehicle + PF-04217329 - Low Dose + Latanoprost Vehicle + PF-04217329 - Middle Dose + Latanoprost Vehicle + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - Low Dose + Latanoprost 0.005% + PF-04217329 - Middle Dose + Latanoprost 0.005% + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - Vehicle

PF-04217329 - Lowest Dose + PF-04217329 - Low Dose + PF-04217329 - Middle Dose + PF-04217329 - High Middle Dose + PF-04217329 - High Dose + PF-4217329 - Highest Dose + PF-04217329 - Vehicle + Latanoprost Vehicle + PF-04217329 - Low Dose + Latanoprost Vehicle + PF-04217329 - Middle Dose + Latanoprost Vehicle + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - Low Dose + Latanoprost 0.005% + PF-04217329 - Middle Dose + Latanoprost 0.005% + PF-04217329 - High Dose + Latanoprost 0.005% + PF-04217329 - Vehicle is a phase 2 stage product being developed by Pfizer for Primary Open-Angle Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00572455. Target conditions include Primary Open-Angle Glaucoma, Ocular Hypertension.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00572455	Phase 2	Completed	Dec 11, 2007	Jun 26, 2009	Primary Open-Angle Glaucoma

Competing Products

20 competing products in Primary Open-Angle Glaucoma

See all competitors

Product	Company	Stage	Hype Score
Unfractionated heparin	Sinopharm	Pre-clinical	22
azenosertib	Zentalis Pharmaceuticals	Phase 2	44
Latanoprost plus adjunctive glaucoma medication	Sight Sciences	Approved	77
REN001	OnKure Therapeutics	Phase 1	25
Mavodelpar + Placebo	OnKure Therapeutics	Phase 2	44
REN001	OnKure Therapeutics	Phase 2/3	57
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo	Skye Bioscience	Phase 2	44
Rituximab + Methotrexate + Cytarabine Injection	Celltrion	Phase 2	52
Rituximab, lenalidomide	Celltrion	Phase 2	52
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RIS	Chugai Pharmaceutical	Phase 3	77
CS-3150	Daiichi Sankyo	Pre-clinical	23
Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin	Daiichi Sankyo	Pre-clinical	23
Bempedoic acid 180 mg tablet	Daiichi Sankyo	Approved	85
Combination of bempedoic acid and ezetimibe	Daiichi Sankyo	Pre-clinical	23
DS-8201a + T-DM1	Daiichi Sankyo	Phase 3	77
Bempedoic acid and/or its fixed dose combination with ezetimibe	Daiichi Sankyo	Pre-clinical	23
Roxadustat + Placebo	Astellas Pharma	Phase 3	77
Enzalutamide + Exemestane	Astellas Pharma	Phase 2	52
Bocidelpar + Placebo	Astellas Pharma	Phase 2	52
Methotrexate + Ibrutinib + Temozolomide	Sun Pharmaceutical	Phase 2	52

Other Products from Pfizer